Name of the Test:
Matrix Metalloproteinase- 9 (MMP-9)
MMP-9 has been shown to be increased in:
Elevated in acute Coronary artery syndromes, type 2 diabetes, patients with various cancers including breast cancer and systemic lupus erythomatosis.
Elevated in alcohol abusers and could be used as a marker for liver fibrosis in patients with chronic hepatitis-C.
Clinical research applications:
Matrix metalloproteinases (MMPs) are a family of Zinc- dependent endopeptidases that degrade extracellular matrix proteins. Human MMP-9 Matrix metalloproteinase-9 (Gelatinase–B), with a molecular weight of 82 Kd, is inhibited by TIMP-1 and alpha 2 macroglobulin. MMP-9 is secreted by tumor cells, endothelial cells, fibroblasts and leucocytes.MMP-9 is involved in inflammation, tissue modeling, wound healing and processing of cytokines. Expression of MMP-9 correlates with abnormal collagen deposition that accompanies pancreatic cancer, with the metastasis to lymph nodes by human breast cancer cells and invasion of regional vessels in giant cell tumors of bones. MMP-9 is elevated in saliva in patients with gingivitis and periodontal diseases.
MMP-9in serum is quantitated using an ELISA (Enzyme linked immunosorbent assay) procedure. It is a two-step sandwich-type immunoassay using two antibodies to MMP-9; monoclonal antibody is the capture antibody and signal polyclonal antibody is conjugated with horse-raddish peroxidase (HRP). High concentration of MMP-9 results in high color reading at 450 nm.
The assay is research use only (RUO), not for clinical application.
Specimen requirements: 1.0 ml (minimum 0.5 ml) of serum.
Shipping requirements: Ship the samples frozen. Shipping samples at room temperature is not accepted.
Turnaround time: Set up every Wednesday and reported the same day.
Reference Range: Less than 900 ng /ml of serum .
1.Ueda Y et al (1996) Matrix metalloproteinase 9(gelatinase B)is expresses in multinucleated giant cells of human giant cell tumor of bone and is associated with vascular invasion Amer. J Pathology 148: 611.
2.Kai H et al ( 1998) Peripheral blood levels of matrix metalloproteinases -2 and -9 are elevated in patients with acute coronary syndromes J Amer Coll. Cardiology 32:368-372.
3.Leroy V et al ( 2004) Circulating Matrix metalloproteinases 1,2,9 and their inhibitors TIMP-1 and TIMP-2 as serum markers on liver fibrosis in patients with chronic hepatitis Amer J Gastroenterology 99: 271-279.